Kantar Health Blog

  • Neesha Suvarna
    Oncology Conference Insight: ASCO 2013 --- The melanoma market has been transformed in the past two years, following the discovery of the BRAF mutations that are observed in approximately 50% of melanoma patients. BRAF mutants are primarily treated with BRAF inhibitor Zelboraf® (vemurafenib, Genentech/Roche) and this area has been a hot bed of research with recent approvals of Tafinlar® (dabrafenib, GSK, another BRAF inhibitor) and Mekinist® (trametinib, GSK, MEK inhibitor).
    Continue Reading > | Go comment! | Share
  • User Not Found
    There has been a fair amount of talk lately about the impact of payment reductions for cancer care services by 2%, and a reduction in reimbursement for buy and bill cancer drugs from ASP + 6% to ASP +4.3. So what is the impact of sequestration on oncology – is it a practice catastrophe, or just a reduction in profits?
    Continue Reading > | Go comment! | Share
  • Biomarkers in Breast Cancer: More Than Just HER2

    by Stephanie Hawthorne | Apr 8, 2013
    Stephanie Hawthorne
    Oncology Conference Insight - AACR 2013 --- On Sunday at the American Association for Cancer Research (AACR) 2013 annual meeting, Jose Baselga presented new data from the Phase III EMILIA trial (Abstract LB-63) that suggested a relationship between tumor biomarkers and efficacy of Kadcyla® (TDM-1, ado-trastuzumab emtansine; Roche/Genentech). Kadcyla is a novel antibody-drug conjugate that comprises a potent microtubule polymerization inhibitor conjugated to the Herceptin® (trastuzumab; Roche / Genentech) monoclonal antibody via a highly stable linker.
    Continue Reading > | Go comment! | Share
  • The Demise of Chemotherapy in Front-Line mCRPC?

    by Neesha Suvarna | Feb 15, 2013
    Neesha Suvarna
    Oncology Conference Insight - ASCO GU 2013 --- The metastatic castrate-resistant prostate cancer (mCRPC) market appears to be on a trajectory toward a relinquishment to novel hormonal agents and a regression of chemotherapy and other targeted therapies to later lines. If Jevtana manages to supersede docetaxel, it may only be a marginal improvement in this field, with a swap of one taxane for another.
    Continue Reading > | Go comment! | Share
  • User Not Found
    Pricing a drug is a hugely important aspect of pre-launch and launch planning as it can directly influence market share. Forecasting the dollar value of an oncology drug presents many challenges and caveats and takes into account price, duration of therapy, the eligible population, and market share of the eligible population.
    Continue Reading > | Go comment! | Share